Bluejay Diagnostics (NASDAQ:BJDX) Trading 0.6% Higher – Should You Buy?

Bluejay Diagnostics, Inc. (NASDAQ:BJDX)’s stock price rose 0.6% on Monday . The stock traded as high as $1.60 and last traded at $1.55. Approximately 838,221 shares were traded during mid-day trading, an increase of 635% from the average daily volume of 114,052 shares. The stock had previously closed at $1.54.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Saturday, September 27th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Bluejay Diagnostics has a consensus rating of “Sell”.

Bluejay Diagnostics Stock Performance

The business has a 50 day simple moving average of $1.47 and a 200-day simple moving average of $1.86. The firm has a market capitalization of $2.31 million, a price-to-earnings ratio of -0.01 and a beta of 0.54.

Bluejay Diagnostics (NASDAQ:BJDX) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($1.41) earnings per share (EPS) for the quarter.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.